1. A randomized, controlled trial of a low-dose contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for acne treatment 
Diane Thiboutot, M.D., David F Archer, M.D., André Lemay, M.D., Ph.D., Ken Washenik, M.D., Ph.D., Janet Roberts, M.D., Diane D Harrison, M.D. 
Fertility and Sterility 
Volume 76, Issue 3, Pages (September 2001)
DOI: /S (01)

2. Figure 1
Mean changes from baseline in (A) total, (B) inflammatory, and (C) noninflammatory lesion counts during treatment with levonorgestrel and ethinyl estradiol (♦) or placebo (□) for six cycles (efficacy population). ∗Significantly different from placebo (P<.05).
Thiboutot. A 20-μg OC for moderate acne treatment. Fertil Steril 2001.
Fertility and Sterility  , DOI: ( /S (01) )

3. Figure 2
Clinician global assessment (CGA) of patient complexion during treatment with levonorgestrel and ethinyl estradiol (♦) or placebo (□) in the efficacy population. Clinicians rated significantly more patients as clear/almost clear in the levonorgestrel and ethinyl estradiol group than in the placebo group. ∗Significantly different from placebo (P<.05).
Thiboutot. A 20-μg OC for moderate acne treatment. Fertil Steril 2001.
Fertility and Sterility  , DOI: ( /S (01) )

4. Figure 3
Mean changes from baseline in weight with levonorgestrel and ethinyl estradiol (▩) and placebo (□). No significant differences in weight were observed between levonorgestrel and ethinyl estradiol treatment and placebo (at cycle 6, P=.50).
Thiboutot. A 20-μg OC for moderate acne treatment. Fertil Steril 2001.
Fertility and Sterility  , DOI: ( /S (01) )